Carbohydrate dependent targeting of cancer cells by bleomycin-microbubble conjugates

Journal of the American Chemical Society

Volumn 131, Issue 7, 2009, Pages 2438-2439

  Chapuis, Jean Charles ^a   Schmaltz, Ryan M ^a,b   Tsosie, Krystal S ^a,c   Belohlavek, Marek ^c   Hecht, Sidney M ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CANCER CELLS; COPPER SUBSTRATES; GROWTH MECHANISMS; HIGH QUALITY; HYBRID PHYSICAL-CHEMICAL VAPOR DEPOSITION; MICRO-BUBBLE; NANO SCALE; SINGLE-CRYSTAL STRUCTURE; TRANSITION TEMPERATURE;

CARBOHYDRATES;

CRYSTAL STRUCTURE;

BLEOMYCIN; CARBOHYDRATE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; BIOTIN; BLEOMYCIN A5; STREPTAVIDIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL STRAIN MCF 7; CONJUGATE; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MICROBUBBLE; MONOLAYER CULTURE; STRUCTURE ANALYSIS; TARGET CELL; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BIOTIN; BLEOMYCIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; MICROBUBBLES; STREPTAVIDIN;

EID: 67749130951     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja8091104     Document Type: Article

References (31)

1. (a) Umezawa, H. Antibiot. Chemother. 1978, 23, 76.
2. (b) Sikic, B. I., Rozencweig, M., Carter, S. K., Eds. Bleomycin Chemotherapy; Academic Press: Orlando, FL, 1985.
3. Levi, J. A.; Raghavan, D.; Harvey, V.;Thompson, D.; Sandeman, T.; Gill, G.; Stuart-Harris, R.; Snyder, R.; Byrne, M.; Kerestes, Z. J. Clin. Oncol. 1993, 11, 1300.
4. (a) Stubbe, J.; Kozarich, J. W. Chem. Rev. 1987, 87, 1107.
5. (b) Kane, S. A.;Hecht, S. M. Prog. Nucleic Acid Res. Mol. Biol. 1994, 49, 313.
6. Claussen, C. A.; Long, E. C. Chem. Rev. 1999, 99, 2797.
7. Hecht, S. M. J. Nat. Prod. 2000, 63, 158.
8. (e) Chen, J.; Stubbe, J. Nat. Rev. 2005, 5, 102.
9. (a) Carter, B. J.; de Vroom, E.; Long, E. C.; van der Marel, G. A.; van Boom, J. H.; Hecht, S. M. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 9373.
10. (b) Holmes, C. E.; Carter, B. J.; Hecht, S. M. Biochemistry 1993, 32, 4293.
11. Hecht, S. M. Bioconjugate Chem. 1994, 5, 513.
12. Abraham, A. T.; Lin, J.-J.; Newton, D. L.; Rybak, S.; Hecht, S. M. Chem. Biol. 2003, 10, 45.
13. (e) Tao, Z.-F.; Konishi, K.; Keith, G.; Hecht, S. M. J. Am. Chem. Soc. 2006, 128, 14806.
14. (a) Jones, S. E.; Lilien, D. L.; O'Mara, R. E.; Durie, B. G.; Salmon, S. E. Med. Ped. Oncol. 1975, 1, 11.
15. (b) Silverstein, M. J.; Verma, R. C.; Greenfield, L.; Morton, D. L. Cancer 1976, 37, 36.
16. van de Poll, M. A.; Versluis, A.; Rasker, J. J.; Jurjens, H.; Woldring, M. G. Nuclear-Medizin 1976, 15, 86.
17. Rasker, J. J.; Beekhuis, H.; van de Wal, A. M.; van der Heide, J. N. H.; Woldring, M. G. Thorax 1976, 31, 641.
18. (e) Oyama, K.; Machida, K.; Watari, T.; Hayashi, S.; Akaike, A. Radioisotopes 1976, 25, 567.
19. (f) Burton, I. E.; Todd, J. H.; Turner, R. L. Brit. J. Radiol. 1977, 50, 508.
20. (g) Tonami, N.; Kobayashi, S.; Maeda, T.; Hisada, K. Jap. J. Nucl. Med 1977, 14, 217.
21. (h) Firusian, N.; Makoski, H. B. Strahlentherapie 1977, 153, 331.
22. Bekerman, C.; Moran, E. M.; Hofer, P. B.; Hendrix, R. W.; Gottschalk, A. Radiology 1977, 123, 687.
23. j) Stern, P. H.; Helpern, S. E.; Hagan, P. L.; Howell, S. B.; Dabbs, J.; Gordon, R. M. J. Nat. Cancer Inst. 1981, 66, 807.
24. (a) DeRiemer, L. H.; Meares, C. F.; Goodwin, D. A.; Diamanti, C. I. J. Med. Chem. 1979, 22, 1019.
25. (b) Goodwin, D. A.; Meares, C. F.; DeRiemer, L. H.; Diamanti, C. I.; Goode, R. L.; Baumert, J. E., Jr.; Sartorius, D. J.; Lantieri, R. L.; Fawcett, H. D. J. Nucl. Med. 1981, 22.
26. Linder, J. Nat. Rev. Drug Discovery 2004, 3, 527.
27. (a) Klibanov, A. Invest. Radiol. 2006, 41, 354.
28. (b) Willmann, J.; Paulmurugan, R.; Chen, K.; Gheysens, O.; Rodriguez-Porcel, M.; Lutz, A.; Chen, I.; Chen, X.; Gambhir, S. Radiology 2008, 246, 508.
29. 18 reversed phase HPLC.
30. 8 streptavidin-derivatized microbubbles was treated with 50 μL of aq. 500 μM BLM 2a or 2b. The combined solution was agitated gently for 20 min, then free BLM was removed by repeated centrifugation (400 × g, 3 min, 10 °C) and washing with buffer.
31. 5-microbubble conjugate was observed using SW480 colon carcinoma cells (but not CRL-1541 colon cells), DU145 prostate carcinoma cells (but not CRL-2221 prostate cells), and A549 lung carcinoma cells (but not CCL-75 lung cells).